iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results



    VANCOUVER, June 26 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased
to provide further preclinical results supporting the accelerated development
of iCo-009, the company's oral reformulation of Amphotericin B (Amp B). Amp B
is a generic drug that has been in use for approximately 50 years, however its
use is limited as it is currently administered intravenously and has
significant infusion related side effects and kidney toxicity.
    The studies were conducted in a rat fungal model of Candida albicans in
the laboratory of Dr. Kishor Wasan at UBC. Kidney and organ colony forming
units (CFU) were used as an indicator of antifungal activity, and kidney
toxicity was indirectly assessed by determining creatinine concentration in
plasma. Significant antifungal activity was seen at dosage levels where no
kidney toxicity was observed. The results will be submitted to a scientific
journal in the coming months.
    "This data serves as further validation of iCo-009's ability to safely
kill fungal infections without the need to intravenously infuse Amphotericin
B," stated Andrew Rae, President & CEO of iCo Therapeutics. "These results not
only corroborate those generated by Dr. Kish Wasan's lab in the rat
Aspergillus fumigatus model, but show an increasingly positive trend."
    iCo-009 has the potential to treat not only systemic fungal infections,
which have emerged as important causes of morbidity and mortality in
immunocompromised patients (e.g., AIDS, cancer chemotherapy, organ or bone
marrow transplantation), but also parasitical diseases such as Leishmaniasis
in the developing world. iCo plans to develop iCo-009 under the 505(b)(2)
section of the Federal Food, Drug, and Cosmetic Act, which expressly permits
the FDA to reference safety data not developed by the applicant for approval
of a New Drug Application (NDA). This approach can potentially reduce the
development time and expense for approval of a drug.

    About iCo Therapeutics

    iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on
redosing or reformulating drugs with clinical history for new or expanded
indications. iCo has exclusive worldwide rights to three products, iCo-007, in
Phase I for the treatment of Diabetic Macular Edema, iCo-008, a product with
Phase II clinical history to be developed for severe ocular allergies, and
iCo-009, an oral reformulation of Amphotericin B for sight and life -
threatening diseases. iCo-009 also represents a new drug delivery technology
with the potential to reprofile other parenteral administered drugs to the
oral route of administration. iCo Therapeutics trades on the TSX-Venture
exchange under the symbol "ICO". For more information, visit the company
website at: www.icotherapeutics.com

    No regulatory authority has approved or disapproved the content of this
release.

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.

    Forward Looking Statements

    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on iCo
Therapeutics' current beliefs as well as assumptions made by and information
currently available to iCo Therapeutics and relate to, among other things,
anticipated financial performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by iCo Therapeutics in its
public securities filings; actual events may differ materially from current
expectations. iCo Therapeutics disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.





For further information:

For further information: Business Development: Dr. John Clement, CT&DO,
(778) 688-0644; Finance Contact: Mr. John Meekison, CFO, (604) 602-9414 x 224;
Investor/Media Contact: Frederica Bell, Corp. Devt., (604) 602-9414 x 228

Organization Profile

iCo Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890